IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is a paper indexed in ScholarIQ from OpenAlex.
How many citations does IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing have?
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has 52 citations in the OpenAlex counts ScholarIQ stores.
When was IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing published?
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has 2023 year in the ScholarIQ index.
What is the open-access status of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?
IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing has hybrid oa status in the ScholarIQ index.
What is the DOI of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?
The DOI for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.
What is the PMID of IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?
The PMID for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.
What is the OpenAlex record for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing?
The OpenAlex for IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing is on the source record.